HIV Treatment Cuts Biological Aging by 4 Years: A Revolutionary Discovery
The recent study presented at ESCMID Global 2026 has revealed a groundbreaking finding in the field of HIV treatment and aging research. Antiretroviral therapy (ART) has been shown to significantly reduce accelerated biological aging in people with HIV (PWH) by nearly four years, a discovery that could revolutionize how clinicians approach HIV management and long-term health outcomes.
The study developed a plasma proteomic aging clock (PAC), a sophisticated tool that estimates biological age based on the analysis of hundreds of blood proteins. This innovative model was applied to participants in the Swiss HIV Cohort Study (SHCS), providing valuable insights into the impact of HIV and ART on aging.
One of the most striking findings was the significant reduction in proteomic age after ART. During untreated HIV infection, the PAC estimated an accelerated biological age of 10 years. However, after a median duration of 1.55 years of ART, researchers observed a remarkable 3.7-year reduction in proteomic age (95% CI 2.7 to 4.7; p = 0.0001). This indicates that sustained ART treatment can effectively slow down the aging process in PWH.
Dr. Barry Ryan, the lead study author, emphasizes the importance of early ART initiation and optimal adherence. The study's unique group from the SHCS, who had samples collected for up to eight years before starting ART, allowed researchers to measure the effects of untreated HIV infection and successful ART on various aging markers. The results consistently demonstrated that uncontrolled HIV infection is associated with faster aging, while ART significantly slows down this process.
The PAC primarily captures changes in inflammatory signaling and drug metabolomic pathways, providing a comprehensive understanding of the aging process in PWH. Interestingly, when compared to the team's previous epigenetic aging clock (EAC), both clocks showed similar overall trends. However, the PAC's sensitivity to short-term immune changes is particularly noteworthy, reflecting a faster increase during untreated infection and a rapid decline once HIV was suppressed with ART.
Importantly, the reversal of proteomic age acceleration after ART was not significantly associated with CD4+ or CD8+ T-cell count recovery. This suggests that the reversal of aging is a result of broader inflammatory and innate immune remodeling, rather than T-cell reconstitution alone. Dr. Ryan highlights the current consensus for starting ART promptly after HIV diagnosis, as the study observed accelerated proteomic aging even in the early stages of infection.
The authors emphasize the need for external validation of the PAC in diverse global populations to ensure its applicability across different ancestries and populations. Additionally, proteome-wide feature attribution studies are required to identify the specific pathways driving HIV-related aging biology. Despite potential variations in reversal pathways, the global trend of accelerated aging with untreated HIV and its attenuation after virological suppression is likely to be widely applicable.
This groundbreaking study highlights the transformative potential of ART in slowing down biological aging in PWH. It underscores the importance of early intervention and optimal adherence to ART, offering a glimmer of hope for improved long-term health outcomes in the HIV community. As research continues to unravel the complex relationship between HIV, aging, and treatment, the future holds promise for more effective and personalized HIV management strategies.
